Company
Eitan Medical
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
1
510(k), De Novo and PMA
Device trials
1
As lead sponsor, any status
Adverse event reports
154
Received Nov 1, 2025 to Nov 20, 2026
Recall records
1
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
From SEC filings.
We found no SEC financing filings under the name Eitan Medical, so its financing is unknown here. That is common for companies based outside the US, for subsidiaries of larger companies, and for companies funded by founders, grants or customers. A company that changed its name can also be missed.
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors from funding announcements and the firms' own portfolio pages.
No 5%+ shareholder filings, SBIR grants or venture investors found under the name Eitan Medical.
Latest FDA decisions
K213744 · Decided Mar 10, 2023 · 466 days after receipt
Device type: Pump, Infusion (FRN) · Hospital Medicine & Nursing
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Sorrel 25R Injector - Sorrel Clinical Study ProtocolStatus unknown
NCT05221333 · 20 participants (planned) · Start Aug 23, 2021 · Primary completion Dec 15, 2022
Device: Sorrel Wearable Injector · For: Injection Site; Injection Site Reaction; Injection Site Irritation
Sites: Philadelphia, Pennsylvania
Reports received
154
Received Nov 1, 2025 to Nov 20, 2026. Includes 3 of another or unstated type.
Malfunction reports
123
80% of reports
Injury reports
28
18% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 4 | 0 | 0 | 0 |
| Jan 24 | 7 | 2 | 0 | 0 |
| Feb 24 | 2 | 1 | 0 | 0 |
| Mar 24 | 6 | 1 | 0 | 0 |
| Apr 24 | 4 | 1 | 0 | 0 |
| May 24 | 4 | 0 | 0 | 0 |
| Jun 24 | 6 | 0 | 0 | 0 |
| Jul 24 | 4 | 2 | 0 | 0 |
| Aug 24 | 8 | 1 | 0 | 0 |
| Sep 24 | 10 | 2 | 0 | 0 |
| Oct 24 | 6 | 0 | 0 | 0 |
| Nov 24 | 1 | 0 | 1 | 0 |
| Dec 24 | 5 | 0 | 0 | 0 |
| Jan 25 | 10 | 1 | 0 | 0 |
| Feb 25 | 6 | 1 | 0 | 0 |
| Mar 25 | 12 | 0 | 0 | 0 |
| Apr 25 | 4 | 3 | 1 | 0 |
| May 25 | 7 | 1 | 0 | 0 |
| Jun 25 | 7 | 0 | 0 | 0 |
| Jul 25 | 3 | 0 | 0 | 0 |
| Aug 25 | 4 | 0 | 0 | 0 |
| Sep 25 | 12 | 0 | 0 | 0 |
| Oct 25 | 8 | 0 | 0 | 0 |
| Nov 25 | 10 | 0 | 0 | 0 |
| Dec 25 | 6 | 0 | 0 | 0 |
| Jan 26 | 7 | 0 | 0 | 0 |
| Feb 26 | 9 | 0 | 0 | 0 |
| Mar 26 | 15 | 2 | 0 | 0 |
| Apr 26 | 10 | 0 | 0 | 0 |
| May 26 | 5 | 0 | 0 | 0 |
| Jun 26 | 5 | 0 | 0 | 0 |
| Jul 26 | 17 | 20 | 0 | 0 |
| Aug 26 | 14 | 2 | 0 | 2 |
| Sep 26 | 13 | 4 | 0 | 0 |
| Oct 26 | 12 | 0 | 0 | 1 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
The full in this ranking with a free account
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
7 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Sapphire Infusion Pumps, Models: Multi-Therapy (REF 15031-000-0028), Epidural (REF 15032-000-0027) and SapphirePlus (REF 15038-000-0001)Open, Classified
Z-0094-2024 · Started Sep 11, 2023 · Posted by FDA Oct 20, 2023
Reason given: Infusion Pumps with affected software revision may fail to detect air in line, which may lead to air embolism.
Cause as FDA categorized it: Software Design Change · Device type: Pump, Infusion (FRN)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.